Meet Our Management Team

Our core management team combines the relevant HIV/AIDS and oncology development experience: Pharmaceutical industry, biotech and academia. We opt for outsourcing manufacturing and regulatory (based on past experience of other biotech companies developing advanced therapies).

Dr. Mark Dybul

Executive Vice Chairman


Dr. Dybul has served as a Professor in the Department of Medicine at Georgetown University Medical Center, and the Faculty Co-Director of the Center for Global Health and Quality since June of 2017. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher, and administrator, most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. Dr. Dybul was one of the founding architects in the formation of the U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical officer, Assistant, Deputy and Acting Director, he was appointed as its leader in 2006, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Earlier in his career, after graduating from Georgetown Medical School in Washington D.C., Dr. Dybul joined the National Institute of Allergy and Infectious Diseases, as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University. Dr. Dybul is a member of the national academy of medicine. We believe Dr. Dybul’s extensive high-level clinical and institutional experience in the field of HIV/AIDS qualifies him to serve as a director.

Luisa Puche

Chief Financial Officer


Luisa Puche, has served as a senior accounting and financial advisor and president of Puche Group, LLC, since 2015. She has served in a variety of advisory capacities for both public and private organizations, such as technical accounting consultations; complex technical implementations, M&A transactions; IT Risk assessments; and SOX 404 implementations. Leveraging her broad global audit, advisory, and corporate expertise, Luisa has provided strong cross-functional leadership experience managing small and large projects for both publicly-traded and privately-held companies in various industries including a global implementation of the latest revenue recognition accounting standard for Del Monte, a $4B publicly traded global fresh produce company, as well as the global implementation of their SOX-404 program.

Previously, Luisa served in various senior executive roles at Brightstar Corp., a $10B global wireless device services provider, with public reporting requirements, including as Vice President and Global Controller and Interim Chief Accounting Officer. During her tenure at the Company she was responsible for the financial reporting of 55 countries, as well as instrumental in various key transactions including an $1.6B European acquisition and the sale of Brightstar to SoftBank. Luisa was also an executive at Ernst & Young, a big 4 accounting firm, where she worked for 10 years.

Highlights of her public company clients include: Del Monte Fresh Produce Company, Royal Palm Venture Capital, Terremark Worldwide, Knight-Ridder, Inc. and Vanguard Car Rental, Inc. (formerly Alamo and National Car Rental).
Luisa holds a Bachelor’s of Accounting from Florida International University. The above qualifies Luisa Puche to serve as CFO.

Tung Nguyen

Director of Molecular Biology


Devoting more than a quarter of a century on research with focus on signal transduction and molecular basic of cancer and infection, Tung is eager to transform his passion for Science into cures for diseases, to fulfill his life-long wish on helping people and saving lives.

He conducted research at the Molecular Oncology Department at John Wayne Cancer Institute, the Molecular Host Defense Laboratory at UCLA and the Molecular Immunology at Beckman Research Institute at City of Hope Medical Center. And “this is exactly where I want to be today …”, he stated upon joining Enochian Biosciences team.

Joseph R. Cohen, Ph.D

Director of Research and Discovery


Dr. Cohen brings over two decades of experience in molecular and cellular biology, brain and hematological cancer biology, immunology, immune-oncology, and both small molecule and cellular cancer immunotherapy from a career spanning the John Wayne Cancer Institute, UCLA, the National Institutes of Health (NCI), the University of Pennsylvania and City of Hope. He has expertise in the areas of translational drug development, analytical assay and process development, GLP, SOP writing, CMC, and FDA and IHC regulations for IND enabling pre-clinical studies for cellular immuno therapies. He has a passion for brain cancer, immune-oncology and cellular immunotherapies, and has devoted his career towards driving translational immunotherapies to help patients suffering from cancer and other diseases. Dr. Cohen holds a B.S. in Biochemistry from the University of Tampa. And he holds a Ph.D. from UCLA in Neuroscience – specializing in the molecular and cellular biology of brain cancer development and therapy. After completing his doctorate at UCLA he received his post-doctoral training at the NIH in cancer molecular and cellular biology, metastasis and immunotherapy in the Laboratory of Tumor Immunology and Biology. Additionally, he brings experience and expertise in pre-clinical translational drug development, for CAR T cell-based immunotherapies from the Center for Cellular Immunotherapies at University of Pennsylvania and the T Cell Therapeutics Research Laboratory at City of Hope, for the treatment of brain and hematological cancers.